Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib.
Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib.
复制标题
NOS3 rs2070744基因型对接受乐伐替尼治疗的肝细胞癌患者的影响
DOI：
10.1038/s41598-020-73930-3
复制
发表时间：
2020-10-13
影响因子：
4.6
通讯作者：
Atsuda K
中科院分区：
文献类型：
--
作者：
Azuma S;Uojima H;Chuma M;Shao X;Hidaka H;Nakazawa T;Kondo M;Numata K;Iwabuchi S;Kako M;Maeda S;Koizumi W;Atsuda K
我们研究了一氧化氮合酶 3 (NOS3) rs2070744 基因型是否会影响肝细胞癌 (HCC) 患者对乐伐替尼治疗的反应。我们评估了 NOS3 rs2070744 基因型与肿瘤反应、无进展生存期 (PFS) 和总生存期 (OS) 之间的关系，作为乐伐替尼的反应。我们还检查了乐伐替尼的潜在特征——成纤维细胞生长因子受体（FGFR）基因多态性与反应之间的关联。尽管 TT 基因型患者的平均 PFS（风险比 [HR] 0.60；p = 0.069）和平均 OS（HR 0.46；p = 0.075）比 TC/CC 基因型患者更长，但研究之间的 PFS 或 OS 没有显着差异。然而，具有 NOS3 rs2070744 TC/CC 和 FGFR4 rs351855 CT/TT 基因型单核苷酸多态性 (SNP) 组合模式的患者的平均 PFS (HR 2.56；p = 0.006) 和平均 OS (HR 3.36；p = 0.013) 明显短于其他患者基因型。 NOS3 rs2070744 基因型不影响临床反应。然而，NOS3 rs2070744 和 FGFR4 rs351855 基因型的 SNP 组合模式可能有助于作为接受仑伐替尼治疗的 HCC 患者的治疗效果预测因子和预后因素。
We investigated whether or not nitric oxide synthase 3 (NOS3) rs2070744 genotypes can affect the response for lenvatinib treatment in patients with hepatocellular carcinoma (HCC). We evaluated the relation of the NOS3 rs2070744 genotypes to the tumor response, progression-free survival (PFS), and overall survival (OS) as the response for lenvatinib. We also examined the association between fibroblast growth factor receptor (FGFR) gene polymorphisms, a potential feature of lenvatinib, and the response. There were no significant differences between the studies for either PFS or OS, even though patients with the TT genotype had a longer mean PFS (hazard ratio [HR] 0.60; p = 0.069) and mean OS (HR 0.46; p = 0.075) than those with the TC/CC genotypes. However, patients with a single-nucleotide polymorphism (SNP) combination pattern of the NOS3 rs2070744 TC/CC and FGFR4 rs351855 CT/TT genotypes had a significantly shorter mean PFS (HR 2.56; p = 0.006) and mean OS (HR 3.36; p = 0.013) than those with the other genotypes. The NOS3 rs2070744 genotypes did not influence the clinical response. However, the SNP combination pattern of the NOS3 rs2070744 and FGFR4 rs351855 genotypes may be helpful as treatment effect predictors and prognostic factors for HCC patients treated with lenvatinib.
登录
查看更多内容
影响因子：
--
作者：
Gardini, Andrea Casadei;Marisi, Giorgia;Frassineti, Giovanni Luca
通讯作者：
Frassineti, Giovanni Luca
影响因子：
0.6
作者：
Diler, S. B.;Oden, A.
通讯作者：
Oden, A.
影响因子：
50.5
作者：
Chen, L-T;Martinelli, E.;Douillard, J-Y
通讯作者：
Douillard, J-Y
影响因子：
6.4
作者：
Ma, Zhiyong;Tsuchiya, Norihiko;Habuchi, Tomonori
通讯作者：
Habuchi, Tomonori
影响因子：
5.2
作者：
Marisi, Giorgia;Petracci, Elisabetta;Casadei-Gardini, Andrea
通讯作者：
Casadei-Gardini, Andrea